Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBD-uN1que
NCT07668856Phase 3Recruiting
- Start
- Feb 2025
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in epilepsy comparing Active treatment with CBD oil with Placebo (2 arms). Primary endpoint: Seizure frequency up to 6 months. Started Feb 2025; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT07668856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07668856.